ClinicalTrials.gg
Enrolling by invitationNCT07920276Updated Nov 5, 2026

Discision as Acceleration Method in Canine Retraction in Orthodontics With Aligner and Fixed Appliances in Young Adults a Split Mouth Study

An interventional study of Discision in Bimaxillary Protrusion and Class II Div 1 Malocclusion, sponsored by Al-Azhar University. Enrolling by invitation at 2 sites in Egypt. Open to participants aged 17 Years to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Al-Azhar University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Feb 2026, registered May 2026).
Updated Nov 5, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
17 Years to 24 Years
Sex
All
01

Study summary

The effectiveness of discision in accelerating orthodontic canine retraction will be evaluated during clear aligner therapy and during conventional fixed orthodontic appliances.

Furthermore, the effectiveness of clear aligner therapy in achieving orthodontic canine retraction will be assessed.

Read the detailed description

Discision means using a disk to cut through the cortical bone inducing regional acceleratory phenomenon (RAP) which may accelerate orthodontic tooth movement (OTM).

02

Conditions studied

  • Bimaxillary Protrusion
  • Class II Div 1 Malocclusion

Keywords

  • Canine retraction
  • Fixed appliances
  • Clear aligners
  • Acceleration of orthodontic tooth movement
  • Discision
03

In context

Malocclusion, Angle Class II

124 studies on the registry are indexed under Malocclusion, Angle Class II; 19 are open to participants now.

This study's planned enrollment of 24 is below the median of 34 across 115 interventional studies indexed under Malocclusion, Angle Class II.

Browse Malocclusion, Angle Class II studies →

Lead sponsor

Al-Azhar University is the lead sponsor of 531 studies on the registry; 172 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
17 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1 - Age from 17 to 24 years old. 2- Fully erupted permanent dentition, 3rd molars excluded. 3- Patients need 1st premolars extraction therapy to achieve class I canine relationship e.g. class I bimaxillary dentoaveolar protrusion or class II division 1 malocclusion with mild or no crowding.

4- Normal shape and structure of maxillary canines, with no history of filling or root canal treatment.

5- Similar degree of minimal crowding on each side of the maxillary arch. 6- Good oral and general health.

Exclusion criteria

Exclusion Criteria:

  1. Impacted canine.
  2. Systemic disease or medications affect bone quality or orthodontic tooth movement.
  3. Craniofacial anomalies, Cleft lip/palate.
  4. lateral open bite or posterior cross bite.
  5. Poor oral hygiene or periodontally compromised patient
  6. History of previous orthodontic treatment
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Group 1. Patients will be treated with clear aligner

    Divided into: Two subgroups by split mouth right and left side randomly. One side with discision and other without.

    Procedure: Discision

  • Experimental
    Group 2. Patients will be treated with fixed appliances

    Divided into: Two subgroups by split mouth right and left side randomly. One side with discision and other side without

    Procedure: Discision

Interventions

  • ProcedureDiscision

    Using a disk saw to make cut it the bone mesial and distal to the canine in one side randomly to accelerate it's movement (retraction).

06

What researchers measure

Primary outcomes

  1. Evaluation of maxillary canine retraction rate in millimeters per week

    Evaluation of maxillary canine retraction with discision in clear aligners verses fixed appliances using cbct

    Time frame: 10 weeks from the beginning of canine retraction.

07

Study locations

2 sites
  • Faculty of dental medicine, Al-Azhar University, Boys, Cairo
    Naşr, Cairo Governorate, Egypt
  • Faculty of dental medicine,Al-Azhar University,Boys,Cairo
    Naşr, Cairo Governorate, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07920276
Responsible party
Ahmed Abd Elrahman Ahmed Selim (Master student, Al-Azhar University) — Principal investigator
First posted
Nov 5, 2026
Start date
Feb 1, 2026
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion